Form 8-K - Current report:
SEC Accession No. 0000950170-25-019866
Filing Date
2025-02-13
Accepted
2025-02-13 16:05:12
Documents
11
Period of Report
2025-02-07
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20250207.htm   iXBRL 8-K 45069
  Complete submission text file 0000950170-25-019866.txt   158743

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20250207.xsd EX-101.SCH 24862
13 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20250207_htm.xml XML 4719
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 25620138
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)